Benzothiophene nucleus in target-directed anti-cancer drug discovery.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• The benzo[b]thiophene scaffold is a privileged structure in anticancer drug discovery.
• Its versatility and sulfur interactions enable selective target binding.

Purpose of the Study:

• To review benzothiophene derivatives as anticancer agents.
• Focus on mechanism-based analysis and validated molecular targets.

Main Methods:

• Literature review of benzothiophene derivatives in cancer research.
• Analysis of compounds targeting kinases, STAT3, estrogen receptor, epigenetics, metabolism, tubulin, and DNA.

Main Results:

• Many derivatives exhibit nanomolar potency and pathway selectivity.
• Demonstrated in vivo anti-tumor activity, improved selectivity, and metabolic stability.
• Raloxifene is the sole approved benzothiophene anticancer drug.

Conclusions:

• Benzothiophenes modulate diverse oncogenic targets effectively.
• Significant therapeutic promise exists, but translational barriers need addressing.
• Structure-activity relationships guide optimization for future anticancer drug development.